Abstract: Described herein are PHD inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of inflammatory bowel disease.
Abstract: Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and compositions, and methods of using these compounds and compositions.
Type:
Grant
Filed:
June 8, 2021
Date of Patent:
August 22, 2023
Assignee:
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Inventors:
Anthony B. Pinkerton, Robert J. Ardecky, Jiwen Zou
Abstract: The pyrrolo[2,3-b]quinoline compounds are antibacterial agents. The emergence of drug-resistant bacteria calls for constant development of new antibacterial agents with the aim of generating medicaments that are potent against drug sensitive and resistant bacteria and are well tolerated. The present compounds are not only new, but have very valuable antimicrobial properties. These compounds showed a broad spectrum of activity against gram-positive and gram-negative bacteria, as well tuberculosis mycobacteria. They also showed potent activity against drug-resistant bacteria, such as MRSA and VRSA. The molecular target of these compounds was identified as DNA Gyrase B. Based on their pharmacological profiles, the present compounds may find important clinical applications for severe infectious diseases and tuberculosis.
Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X—Y—Z??(I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.
Type:
Grant
Filed:
July 29, 2022
Date of Patent:
August 15, 2023
Assignee:
Storm Therapeutics Limited
Inventors:
Wesley Peter Blackaby, Elizabeth Jane Thomas, David James Hardick, Jon Shepherd, Frederick Arthur Brookfield, Christian Bubert, Mark Peter Ridgill
Abstract: This invention relates to heterocyclic compounds and their use in medicine. In particular, the present invention discloses heterocyclic compound of formula I, or an isotopically labeled compound thereof, or an optical isomer thereof, a geometric isomer thereof, a tautomer thereof or a mixture of various isomers, or a pharmaceutically acceptable salt thereof, or a prodrug thereof. The invention also relates to the use of these compounds in medicine.
Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
Type:
Grant
Filed:
November 30, 2022
Date of Patent:
August 8, 2023
Assignees:
AMGEN INC., Vigil Neuroscience, Inc.
Inventors:
Lara C. Czabaniuk, Timothy Hopper, Jonathan B. Houze, Gwenaella Rescourio, Vincent Santora, Haoxuan Wang, Ryan D. White, Alice R. Wong, Yongwei Wu
Abstract: Compounds having activity as inhibitors of NEK7 are provided. The compounds have Structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein, A, X, Y, R1, R2, R3, R4 and R5 are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of the NLRP3 inflammasome are also provided.
Type:
Grant
Filed:
September 14, 2021
Date of Patent:
August 1, 2023
Assignee:
HALIA THERAPEUTICS, INC.
Inventors:
David James Bearss, John Sai Keong Kauwe, III, Alexis Henri Abel Mollard
Abstract: Disclosed herein are methods and processes of preparing vadadustat and pharmaceutically acceptable salts thereof, and intermediates of formula (I) and their salts useful for the synthesis of vadadustat.
Type:
Grant
Filed:
May 8, 2019
Date of Patent:
August 1, 2023
Assignee:
Akebia Therapeutics, Inc.
Inventors:
Boris I. Gorin, Christopher M. Lanthier, Anne Buu Chau Luong, James Densmore Copp, Javier Gonzalez
Abstract: Small molecule stimulators of steroid receptor coactivator-3 (SRC-3) and methods of their use as cardioprotective agents are provided. The small molecule stimulators are useful for promoting cardiac protection and repair and vascular regeneration after myocardial infarction. The compounds are also useful in preventing cardiac hypertrophy and collagen deposition and improving cardiac post-infarction function.
Type:
Grant
Filed:
September 24, 2020
Date of Patent:
July 25, 2023
Assignee:
Baylor College of Medicine
Inventors:
Bert W. O'Malley, David Michael Lonard, Yongcheng Song
Abstract: A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.
Type:
Grant
Filed:
March 17, 2021
Date of Patent:
July 18, 2023
Assignee:
Gilead Sciences, Inc.
Inventors:
Stephen Ammann, Elizabeth M. Bacon, Gediminas Brizgys, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Marilyn Ndukwe, Marina Shatskikh, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
Abstract: The present invention is generally directed to inhibitors of BCL-2 proteins useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I):
Type:
Grant
Filed:
March 11, 2022
Date of Patent:
July 11, 2023
Assignee:
Eil Therapeutics, Inc.
Inventors:
Volodymyr Kysil, Vladislav Zenonovich Parchinsky, Alexei Pushechnikov, Alexandre Vasilievich Ivachtchenko, Ruben Abagyan, Andrew Orry, Polo Chun-Hung Lam, Nikolay Savchuk
Abstract: The disclosure provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The disclosure also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal inflammatory diseases.
Type:
Grant
Filed:
November 24, 2020
Date of Patent:
July 11, 2023
Assignee:
THERAVANCE BIOPHARMA R&D IP, LLC
Inventors:
Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Diana Jin Wang, Anthony Francesco Palermo, Luke Boralsky, Breena Fraga
Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
Type:
Grant
Filed:
February 5, 2021
Date of Patent:
July 11, 2023
Assignee:
BioSplice Therapeutics, Inc.
Inventors:
John Hood, David Mark Wallace, Sunil Kumar KC
Abstract: Pyrazolopyridinone compounds, the pharmaceutical compositions comprising said compounds, and the use of said compounds as FGFR (fibroblast growth factor receptor) inhibitors and their use in the treatment of diseases, e.g. cancer.
Abstract: The present application provides naphthyridinone compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Type:
Grant
Filed:
June 17, 2021
Date of Patent:
July 4, 2023
Assignee:
Incyte Corporation
Inventors:
Stacey Shepard, Lixin Shao, Liangxing Wu, Wenqing Yao
Abstract: This invention relates to compounds of general Formula I and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
Type:
Grant
Filed:
April 30, 2021
Date of Patent:
June 27, 2023
Assignee:
PFIZER INC.
Inventors:
Joyann Barber, Sujin Cho-Schultz, Matthew L. Del Bel, Rebecca Anne Gallego, Mingying He, Mehran Jalaie, Robert Steven Kania, Michele Ann McTigue, Sajiv Krishnan Nair, Anne-Marie Dechert Schmitt, Jamison Bryce Tuttle, Dahui Zhou, Ru Zhou
Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
Type:
Grant
Filed:
August 12, 2020
Date of Patent:
June 27, 2023
Assignee:
OcuTerra Therapeutics, Inc.
Inventors:
Ben C. Askew, Richard W. Heidebrecht, Takeru Furuya, Mark E. Duggan, D. Scott Edwards
Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
Type:
Grant
Filed:
July 22, 2019
Date of Patent:
June 13, 2023
Assignee:
REVOLUTION MEDICINES, INC.
Inventors:
Adrian Gill, Naing Aay, Kevin Mellem, Andreas Buckl, Elena S. Koltun, Christopher Semko, Gert Kiss
Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, Y, W, A, X, m and n are as defined herein, compositions including the compounds and methods of using the compounds.
Type:
Grant
Filed:
September 28, 2020
Date of Patent:
June 13, 2023
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Jérôme Hert, Daniel Hunziker, Patrizio Mattei, Markus Rudolph, Petra Schmitz, Patrick Di Giorgio
Abstract: The present invention aims to find a pharmaceutical preparation which treats or prevents glaucoma or ocular hypertension and is effective for patients with inadequate efficacies of glaucoma or ocular hypertension therapeutic agents. It has been found that omidenepag, an ester thereof, or a salt thereof has an excellent intraocular pressure lowering efficacy on patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents. Therefore, the omidenepag, the ester thereof, or the salt thereof of the present invention is useful as a pharmaceutical preparation which can treat or prevent glaucoma or ocular hypertension even in patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents.